Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria, Australia.
J Neurochem. 2019 Nov;151(3):301-315. doi: 10.1111/jnc.14844. Epub 2019 Aug 26.
Allosteric modulators of metabotropic glutamate receptor 5 (mGlu ) are a promising therapeutic strategy for a number of neurological disorders. Multiple mGlu -positive allosteric modulator (PAM) chemotypes have been discovered that act as either pure PAMs or as PAM-agonists in recombinant and native cells. While these compounds have been tested in paradigms of receptor activation, their effects on receptor regulatory processes are largely unknown. In this study, acute desensitization of mGlu mediated intracellular calcium mobilization by structurally diverse mGlu orthosteric and allosteric ligands was assessed in human embryonic kidney 293 cells and primary murine neuronal cultures from both striatum and cortex. We aimed to determine the intrinsic efficacy and modulatory capacity of diverse mGlu PAMs [(R)-5-((3-fluorophenyl)ethynyl)-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide (VU0424465), N-cyclobutyl-6-((3-fluorophenyl)ethynyl)picolinamide (VU0360172), 1-(4-(2,4-difluorophenyl)piperazin-1-yl)-2-((4-fluorobenzyl)oxy)ethanone (DPFE), ((4-fluorophenyl) (2-(phenoxymethyl)-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)-yl)methanone) (VU0409551), 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB)] on receptor desensitization and whether cellular context influences receptor regulatory processes. Only VU0424465 and VU0409551 induced desensitization alone in human embryonic kidney 293-mGlu cells, while all PAMs enhanced (S)-3,5-dihydroxyphenylglycine (DHPG)-induced desensitization. All mGlu PAMs induced receptor desensitization alone and enhanced DHPG-induced desensitization in striatal neurons. VU0424465 and VU0360172 were the only PAMs that induced desensitization alone in cortical neurons. With the exception of (CDPPB), PAMs enhanced DHPG-induced desensitization in cortical neurons. Moreover, differential apparent affinities, efficacies, and cooperativities with DHPG were observed for VU0360172, VU0409551, and VU0424465 when comparing receptor activation and desensitization in a cell type-dependent manner. These data indicate that biased mGlu allosteric modulator pharmacology extends to receptor regulatory processes in a tissue dependent manner, adding yet another layer of complexity to rational mGlu drug discovery.
变构调节剂的代谢型谷氨酸受体 5 (mGlu ) 是一种很有前途的治疗策略,为许多神经疾病。多种 mGlu 阳性变构调节剂(PAM)化学型已被发现,它们在重组和天然细胞中既可以作为纯 PAMs 也可以作为 PAM-激动剂发挥作用。虽然这些化合物已经在受体激活的范例中进行了测试,但它们对受体调节过程的影响在很大程度上仍然未知。在这项研究中,在人胚肾 293 细胞和纹状体和皮层的原代小鼠神经元培养物中评估了结构多样的 mGlu 正位和变构配体对 mGlu 介导的细胞内钙动员的急性脱敏作用。我们的目的是确定不同 mGlu PAMs 的内在效力和调节能力[(R)-5-((3-氟苯基)乙炔基)-N-(3-羟基-3-甲基丁-2-基)吡啶酰胺(VU0424465)、N-环丁基-6-((3-氟苯基)乙炔基)吡啶酰胺(VU0360172)、1-(4-(2,4-二氟苯基)哌嗪-1-基)-2-((4-氟苄基)氧基)乙酮(DPFE)、(4-氟苯基)(2-(苯氧甲基)-6,7-二氢恶唑并[5,4-c]吡啶-5(4H)-基)甲酮)(VU0409551)、3-氰基-N-(1,3-二苯基-1H-吡唑-5-基)苯甲酰胺(CDPPB)]对受体脱敏的影响,以及细胞环境是否会影响受体调节过程。只有 VU0424465 和 VU0409551 单独在人胚肾 293-mGlu 细胞中诱导脱敏,而所有 PAMs 均增强(S)-3,5-二羟苯甘氨酸(DHPG)诱导的脱敏。所有 mGlu PAMs 均单独诱导脱敏,并增强 DHPG 诱导的脱敏纹状体神经元。VU0424465 和 VU0360172 是仅在皮质神经元中单独诱导脱敏的两种 PAMs。除(CDPPB)外,PAMs 增强了皮质神经元中 DHPG 诱导的脱敏。此外,当以细胞类型依赖性方式比较受体激活和脱敏时,观察到 VU0360172、VU0409551 和 VU0424465 与 DHPG 的差异表观亲和力、效力和协同作用。这些数据表明,变构调节剂的偏态药理学以组织依赖性的方式扩展到受体调节过程,为合理的 mGlu 药物发现增加了另一层复杂性。